Merck & Co. Inc. (NYSE: MRK) has joined the fight against COVID-19, after the company announced that it would be acquiring OncoImmune in an all-cash transaction. The deal is subject to regulatory approval and customary closing conditions, but it is expected to close before the end of 2020.
Under the terms of the deal, Pfizer will make an upfront payment of $425 million in cash for the clinical-stage biopharmaceutical company.
For those late to the party, OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19.
In terms of the specifics from this late-stage study, the interim analysis from the 203 participants indicated that patients with severe or critical COVID-19 treated with a single dose of CD24Fc showed a 60% higher probability of improvement in clinical status, as defined by the protocol, compared to placebo. The risk of death or respiratory failure was reduced by more than 50%.
Also under the agreement, prior to the completion of the acquisition, OncoImmune will spin out certain rights and assets unrelated to the CD24Fc program to a new entity to be owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck will invest $50 million and become a minority shareholder in the new entity.
Merck’s management noted that recent clinical investigations support the view that CD24Fc may provide benefit beyond standard of care therapy for COVID-19 patients requiring oxygen support, and hence will represent an important addition to the Merck pipeline of investigational medicines and vaccines designed to address the COVID-19 pandemic.
Excluding Monday’s move, Merck stock had underperformed the broad markets with a retreat of about 11.5% year to date. In the past 52 weeks, the share price was closer to 6% lower.
Merck stock traded up fractionally early Monday at $80.66, in a 52-week range of $65.25 to $92.64. The consensus price target is $95.58.
24/7 Wall St.The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
